Smith Group Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Smith Group Asset Management LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,800 shares of the biopharmaceutical company’s stock, valued at approximately $770,000.

Several other large investors also recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $26,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the period. Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $51,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth $30,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 1,237.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 297 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $286.91 on Tuesday. The business has a 50-day moving average of $274.68 and a 200-day moving average of $223.34. The stock has a market capitalization of $36.29 billion, a price-to-earnings ratio of -107.06 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period last year, the company posted ($2.21) earnings per share. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. Finally, Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $290.86.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,398 shares of company stock valued at $13,595,460. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.